Abivax SA - American Depositary Shares (ABVX) closed at $87.00 on October 27, 2026, up 0.6% from the previous close, on volume of 731,967 shares (30-day average 1,286,136).
Data as of October 27, 2026.
27-Oct-2026
Market Chameleon (Thu, 1-Oct 3:10 AM ET)
Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026
Globe Newswire (Wed, 30-Sep 4:05 PM ET)
Abivax Presents Business Updates and First Half 2026 Financial Results
Globe Newswire (Mon, 21-Sep 4:05 PM ET)
Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod
Globe Newswire (Thu, 30-Jul 4:05 PM ET)
Market Chameleon (Thu, 2-Jul 7:44 AM ET)
Market Chameleon (Tue, 30-Jun 6:29 AM ET)
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.
Abivax SA - American Depositary Shares trades on the NASDAQ stock market under the symbol ABVX.
As of October 27, 2026, ABVX stock price climbed to $87.00 with 731,967 million shares trading.
ABVX has a beta of 1.83, meaning it tends to be more sensitive to market movements. ABVX has a correlation of 0.09 to the broad based SPY ETF.
ABVX has a market cap of $7.62 billion. This is considered a Mid Cap stock.
Last quarter Abivax SA - American Depositary Shares reported $3 million in Revenue and -$2.43 earnings per share. This beat revenue expectation by $1 million and missed earnings estimates by -$1.35.
In the last 3 years, ABVX traded as high as $148.83 and as low as $4.77.
The top ETF exchange traded funds that ABVX belongs to (by Net Assets): IBB, ORR, MSSM, ONEQ, FRTY.
ABVX has underperformed the market in the last year with a return of -4.1%, while the SPY ETF gained +14.8%. In the last 3 month period, ABVX fell short of the market, returning -30.8%, while SPY returned +4.4%. However, in the most recent 2 weeks ABVX has outperformed the stock market by returning +0.1%, while SPY returned -1.1%.
ABVX support price is $83.96 and resistance is $89.04 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABVX shares will trade within this expected range on the day.
